Aveanna director Robert Williams Jr. sells $192.6m in shares By Investing.com

Robert M. Williams Jr., a director and 10% owner of Aveanna Healthcare Holdings, Inc. (), reported the sale of 16,750,002 shares of common stock across multiple transactions on August 20 and 21, 2026. The total value of these sales amounted to approximately $192.6 million. The timing of the sale is notable, as AVAH shares have surged 84% over the past year and are currently trading at $13.70, well above the $11.50 sale price. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value and is trading near its 52-week high of $13.98.

All shares were sold at a price of $11.50 per share through various entities with which Mr. Williams Jr. is associated.

On August 20, 2026, the following sales occurred as part of an underwritten secondary offering:

J.H. Whitney VII, L.P. sold 10,112,125 shares, valued at approximately $116,289,437.

PSA Healthcare investment Holding LLC sold 957,918 shares, totaling approximately $11,016,057.

JHW Iliad Holdings, LLC sold 1,813,795 shares, amounting to approximately $20,858,642.

PSA Iliad Holdings LLC sold 1,426,034 shares, for a total of approximately $16,399,391.

JHW Iliad Holdings II, LLC sold 190,130 shares, valued at approximately $2,186,495.

An additional sale took place on August 21, 2026, where PSA Healthcare investment Holding LLC sold 2,250,000 shares. This transaction, part of an option to purchase additional shares in the underwritten secondary offering, was valued at approximately $25,875,000. For deeper insights into AVAH’s valuation and performance, InvestingPro offers access to 12 additional ProTips and comprehensive Pro Research Reports covering over 1,400 US equities.

Mr. Williams Jr. is a Managing Member of Equity Partners VII, a Member of Project Iliad, and a Senior Managing Director of Capital Partners. As a result, he may be deemed to share voting and dispositive power over the shares held by these entities, though he disclaims beneficial ownership beyond his pecuniary interest.

In other recent news, Aveanna Healthcare Holdings reported a strong performance for the second quarter of 2026, with revenue reaching $670.5 million, surpassing the forecast of $638.62 million. This represents a 13.7% increase from the previous year, highlighting broad-based growth across its operations. The company also raised its full-year outlook, reflecting strong demand across all three of its business segments. In response to these results, Raymond James raised its price target for Aveanna Healthcare to $15.00 from $13.00, maintaining a Strong Buy rating.

Additionally, RBC Capital adjusted its price target for Aveanna Healthcare to $16.00 from $10.00, citing a California private duty nursing rate increase effective in January 2027 and the company’s strategic positioning related to the Ensuring Access to Medicaid Services rule. In contrast, the company recently announced a secondary offering of 15 million shares of common stock by certain selling stockholders, including affiliates of J.H. Whitney Equity Partners VII, LLC, and certain current and former directors and officers. The underwriter has a 30-day option to purchase up to an additional 2.25 million shares from certain J.H. Whitney affiliates. These developments indicate a period of significant activity and interest in Aveanna Healthcare’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.